Selank: Anxiolytic Peptide Research and GABAergic Modulation
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
# Selank: Anxiolytic Peptide Research and GABAergic Modulation
For Research Purposes Only — Not Intended for Human or Animal Consumption
Introduction
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a tuftsin analogue — tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) with immunomodulatory properties. Selank extends tuftsin with a Pro-Gly-Pro sequence that confers metabolic stability and additional pharmacological properties.
Selank has been approved in Russia for the treatment of generalized anxiety disorder and as a nootropic agent. It has been studied primarily by Russian research groups, which limits independent replication of the published findings.
Mechanism of Action
GABAergic modulation: The primary proposed mechanism of Selank's anxiolytic effects is modulation of GABA-A receptor function. Semenova et al. (2010) demonstrated that Selank increases the expression of GABA-A receptor subunits in rat brain, enhancing GABAergic inhibitory tone. This mechanism is similar to benzodiazepines, which also act at GABA-A receptors, but Selank does not bind to the benzodiazepine binding site and does not produce the sedation, tolerance, or dependence associated with benzodiazepines.
BDNF upregulation: Selank has been shown to increase BDNF expression in the hippocampus and frontal cortex of rats. This BDNF upregulation may contribute to both the anxiolytic effects (BDNF supports hippocampal function and stress resilience) and the cognitive-enhancing effects reported in animal studies.
Enkephalin degradation inhibition: Selank inhibits the degradation of enkephalins (endogenous opioid peptides) by inhibiting enkephalinase enzymes. Elevated enkephalin levels may contribute to anxiolytic and mood-stabilizing effects through opioid receptor activation.
Serotonin modulation: Some studies have reported effects of Selank on serotonin metabolism, including increased serotonin turnover in limbic structures. The relationship between these serotonergic effects and the anxiolytic mechanism is not fully characterized.
Pharmacokinetics
Selank is rapidly degraded by serum peptidases when administered intravenously, with a half-life of minutes. It is typically administered intranasally in Russian clinical practice, which provides direct access to the olfactory epithelium and potentially to the CNS via the olfactory nerve pathway, bypassing the blood-brain barrier.
The intranasal route of administration is pharmacokinetically advantageous for CNS-active peptides because it avoids first-pass metabolism and the blood-brain barrier. However, the fraction of intranasally administered Selank that reaches the CNS versus systemic circulation is not well-characterized.
Clinical Evidence
Selank has been evaluated in clinical trials in Russia for generalized anxiety disorder. Zozulya et al. (2001) reported that Selank produced anxiolytic effects comparable to medazepam (a benzodiazepine) in patients with generalized anxiety disorder, without the sedation or cognitive impairment associated with benzodiazepines.
The clinical evidence is limited by: - Concentration of research in Russian institutions with limited independent replication - Small sample sizes in published trials - Limited long-term safety data - Regulatory approval only in Russia (not FDA or EMA approved)
Comparison with Semax
Selank and Semax are frequently studied together as complementary peptides — Semax for cognitive enhancement and Selank for anxiety reduction. The combination is mechanistically rational because: - Both upregulate BDNF (potentially additive effects) - Selank's anxiolytic effects may enhance the cognitive benefits of Semax by reducing anxiety-related cognitive impairment - The two compounds target different primary mechanisms (Semax: melanocortin/BDNF; Selank: GABAergic/BDNF)
References
- Semenova, T.P., et al. (2010). Selank modulates GABA-A receptor expression in the rat brain. Doklady Biochemistry and Biophysics, 432(1), 127–129.
- Zozulya, A.A., et al. (2001). The comparitive study of the anxiolytic activity of Selank and medazepam in patients with generalized anxiety disorder. Zhurnal Nevrologii i Psikhiatrii, 101(6), 15–19.
- Dolotov, O.V., et al. (2006). Semax and Selank regulate BDNF expression in the rat hippocampus. Brain Research, 1117(1), 54–60.